Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Dr. Ran Reshef
Phone
212-342-0530
Email
rr3036@columbia.edu
(Biography not available)
Clinical Studies Managed By Dr. Reshef:
More InfoTitleSponsorIRB Number
DetailsA study for patients with acute graft host disease (GVHD) following bone marrow transplant using study drug NatalizumabIcahn School of Medicine at Mount SinaiAAAQ8173
DetailsA study for patients with chronic Graft Versus Host Disease (cGVHD) using study drug IbrutinibPharmacyclics LLC.AAAR1134
DetailsStudy of EBV-Cytotoxic T Lymphocytes (EBV-CTLs) in Patients with Epstein-Barr Virus-Associated Viremia or MalignanciesAtara Biotherapeuticcs, Inc.AAAR0039
DetailsStudy of EBV-CTLs in Patients with Epstein-Barr Virus-Associated Viremia or LymphomaAtara Biotherapeuticcs, Inc.AAAR0039
DetailsStudy of Drug for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative DiseaseAtara Biotherapeutics, Inc.AAAR0163
DetailsStudy of Drug for the Treatment of Cytomegalovirus (CMV) Infection in Stem Cell Transplant RecipientsShire ViroPharma, Inc.AAAR2859